TTK Healthcare Limited (TTKHLTCARE) AI Stock Analysis

• Market Cap: ₹16.17B
• Dividend Yield: 0.87%
• Average Volume (3M): 312.00
• Price to Earnings (P/E): 25.6
• Beta (1Y): 0.74
• Revenue Growth: 8.10%
• EPS Growth: -19.89%
• Country: IN
• Employees: 1,316
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - General
• EPS (TTM): 9.20
• Shares Outstanding: 14,130,333
• 10 Day Avg. Volume: 321
• 30 Day Avg. Volume: 312
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,406.00
• Price Target Upside: 22.87% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: ₹1,406.00 ▲(22.87% Upside)

TTK Healthcare Limited's stock score is driven primarily by strong financial performance and stable revenue growth. While the balance sheet is a key strength, cash flow challenges and a neutral technical outlook slightly temper the overall score. The moderate valuation and lack of earnings call or corporate events data also influence the assessment.

TTK Healthcare Limited Business Overview & Revenue Model

Company Description

TTK Healthcare Limited (TTKHLTCARE) is a diversified healthcare company based in India. It operates across various sectors, including pharmaceuticals, consumer products, medical devices, and biotechnology. The company offers a wide range of products such as over-the-counter medications, prescription drugs, medical devices, and personal care products, focusing on improving health and wellness.

How the Company Makes Money

TTK Healthcare Limited generates revenue through multiple streams. Its primary source of income is the sale of pharmaceuticals and over-the-counter products, which are distributed through a vast network of pharmacies, hospitals, and healthcare providers. The company also earns revenue from its consumer product line, which includes personal care and hygiene products sold through retail outlets and online platforms. Additionally, TTK Healthcare benefits from partnerships and collaborations with other healthcare entities, enhancing its product offerings and market reach. Research and development initiatives also play a crucial role in introducing innovative products, thereby supporting long-term revenue growth.

TTK Healthcare Limited Financial Statement Overview

Summary

TTK Healthcare Limited shows strong revenue growth and financial stability with a healthy balance sheet and high ROE. However, negative cash flow figures indicate challenges in cash management, which need to be addressed.

Income Statement

TTK Healthcare Limited has demonstrated a strong revenue growth trajectory, with a notable increase in total revenue from 2024 to 2025. The gross profit margin is robust, showcasing effective cost management. However, the declining EBITDA margin suggests potential increases in operational costs or inefficiencies.

Balance Sheet

The company maintains a healthy balance sheet with a low debt-to-equity ratio and a strong equity ratio, indicating financial stability and low leverage. The high ROE reflects efficient use of equity to generate profits.

Cash Flow

Cash flow analysis reveals challenges, with negative free cash flow and operating cash flow figures. Although there is an improvement in free cash flow growth year-on-year, the negative operating cash flow to net income ratio highlights ongoing cash management issues.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2021	Mar 2022
Income Statement
Total Revenue	8.73B	7.48B	7.25B	6.33B	5.96B
Gross Profit	5.04B	2.63B	3.77B	3.79B	3.09B
EBITDA	1.06B	999.35M	796.81M	373.52M	406.58M
Net Income	816.57M	628.42M	6.40B	464.41M	415.88M
Balance Sheet
Total Assets	12.81B	12.01B	11.70B	4.94B	5.59B
Cash, Cash Equivalents and Short-Term Investments	7.86B	8.45B	8.71B	2.27B	2.73B
Total Debt	242.19M	228.11M	273.29M	191.44M	222.13M
Total Liabilities	2.16B	2.00B	2.17B	2.00B	2.29B
Stockholders Equity	10.65B	10.01B	9.53B	2.95B	3.30B
Cash Flow
Free Cash Flow	-168.16M	-153.27M	-377.75M	946.88M	385.02M
Operating Cash Flow	-39.76M	-49.43M	-260.76M	964.21M	449.96M
Investing Cash Flow	201.03M	284.94M	329.59M	-772.39M	-305.47M
Financing Cash Flow	-180.81M	-219.11M	-124.26M	-171.56M	-91.40M

TTK Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1144.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TTKHLTCARE, the sentiment is Negative. The current price of 1144.3 is below the 20-day moving average (MA) of 1240.31, below the 50-day MA of 1267.22, and below the 200-day MA of 1296.31, indicating a bearish trend. The MACD of -43.33 indicates Positive momentum. The RSI at 32.71 is Neutral, neither overbought nor oversold. The STOCH value of 22.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TTKHLTCARE.

TTK Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WINDLAS	74 Outperform	₹20.10B	30.71		0.63%	20.19%	8.71%
VIMTALABS	72 Outperform	₹27.11B	36.58		0.16%	15.84%	79.69%
AMRUTANJAN	70 Outperform	₹19.64B	35.61		0.68%	8.20%	28.18%
TTKHLTCARE	67 Neutral	₹16.17B	25.63		0.87%	8.10%	-19.89%
SMSPHARMA	61 Neutral	₹20.42B	26.99		0.18%	10.29%	26.79%
BAJAJHCARE	52 Neutral	₹14.64B	32.28		0.22%	17.50%	―
Sector *	47 Neutral	C$212.69M	-1.55	-24.82%	3.11%	19.75%	0.14%